arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Arcadia Biosciences, Inc.

RKDA
$0.14 ▼ -0.02 (-11.67%) at close
Energy ·Crude Petroleum & Natural Gas ·USCrude Petroleum & Natural Gas
51 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcadia Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -0.8% ↗
Op. Margin -34.4% ↗
ROIC None
FCF / Share $-0.11 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.44M
↓ -0.8% —
Net Income Profit after all expenses
$-6.27M
↓ -40.6% —
Operating Margin Operating profit as % of sales
-34.4%
↑ +51.5% 5th
FCF / Share Free cash flow per share
$-0.11
↑ +79.8% —
Long-Term Debt Long-term obligations
$114.00K
↓ -90.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Cash Quality ↑
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 13 years · 51 quarters